These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1128 related articles for article (PubMed ID: 25885683)
1. Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions. Lee SH; Song IH; Noh R; Kang HY; Kim SB; Ko SY; Lee ES; Kim SH; Lee BS; Kim AN; Chae HB; Kim HS; Lee TH; Kang YW; Lee JD; Lee HY BMC Cancer; 2015 Apr; 15():236. PubMed ID: 25885683 [TBL] [Abstract][Full Text] [Related]
2. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma. Cho JY; Paik YH; Lim HY; Kim YG; Lim HK; Min YW; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC Liver Int; 2013 Jul; 33(6):950-7. PubMed ID: 23601249 [TBL] [Abstract][Full Text] [Related]
3. Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib. Inghilesi AL; Gallori D; Antonuzzo L; Forte P; Tomcikova D; Arena U; Colagrande S; Pradella S; Fani B; Gianni E; Boni L; Laffi G; Di Costanzo F; Marra F World J Gastroenterol; 2014 Jan; 20(3):786-94. PubMed ID: 24574751 [TBL] [Abstract][Full Text] [Related]
4. Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study. Nakano M; Tanaka M; Kuromatsu R; Nagamatsu H; Tajiri N; Satani M; Niizeki T; Aino H; Okamura S; Iwamoto H; Shimose S; Shirono T; Koga H; Torimura T; Cancer Med; 2015 Dec; 4(12):1836-43. PubMed ID: 26471348 [TBL] [Abstract][Full Text] [Related]
5. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Bruix J; Takayama T; Mazzaferro V; Chau GY; Yang J; Kudo M; Cai J; Poon RT; Han KH; Tak WY; Lee HC; Song T; Roayaie S; Bolondi L; Lee KS; Makuuchi M; Souza F; Berre MA; Meinhardt G; Llovet JM; Lancet Oncol; 2015 Oct; 16(13):1344-54. PubMed ID: 26361969 [TBL] [Abstract][Full Text] [Related]
6. [Therapeutic decisions in the treatment of hepatocellular carcinoma and patterns of sorafenib use. Results of the international observational GIDEON trial in Spain]. Turnes J; Díaz R; Hernandez-Guerra M; Gómez M; Castells L; Bustamante J; Espinosa MD; Fernández-Castroagudín J; Serrano T; Rendón P; Andrade R; Salgado M; Arenas J; Vergara M; Sala M; Polo BA; Granizo IM; Gonzálvez ML; Viudez A Gastroenterol Hepatol; 2015 Apr; 38(4):263-73. PubMed ID: 25583146 [TBL] [Abstract][Full Text] [Related]
7. Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma. Yada M; Masumoto A; Motomura K; Tajiri H; Morita Y; Suzuki H; Senju T; Koyanagi T World J Gastroenterol; 2014 Sep; 20(35):12581-7. PubMed ID: 25253961 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: age is not a problem. Ziogas DC; Papadatos-Pastos D; Thillai K; Korantzis I; Chowdhury R; Suddle A; O'Grady J; Al-Khadimi G; Allen N; Heaton N; Ross PJ; Sarker D Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):48-55. PubMed ID: 27623000 [TBL] [Abstract][Full Text] [Related]
9. Sorafenib in the treatment of hepatocellular carcinoma: a multi-centre real-world study. Doyle A; Marsh P; Gill R; Rodov M; Mohsen W; Varma P; Hong T; Strasser SI; Bell S; Ryan M; Nicoll A; Lubel J; Gow PJ; Fink MA; Roberts S; Kemp W; Kronborg I; Arachchi N; Knight V; Dev A Scand J Gastroenterol; 2016 Aug; 51(8):979-85. PubMed ID: 27161568 [TBL] [Abstract][Full Text] [Related]
10. Outcomes of treatment with sorafenib in Egyptian patients with hepatocellular carcinoma: a retrospective cohort study. Nada Y; Rashad N; Eissa M; Ghonaim A; Farag K; Saadawi I; Sheha A; El Gewaity M; Abdel-Rahman O Expert Rev Gastroenterol Hepatol; 2018 Jan; 12(1):99-107. PubMed ID: 29124987 [TBL] [Abstract][Full Text] [Related]
11. HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma. Lin SM; Lu SN; Chen PT; Jeng LB; Chen SC; Hu CT; Yang SS; Le Berre MA; Liu X; Mitchell DY; Prins K; Grevel J; Peña CA; Meinhardt G Hepatol Int; 2017 Mar; 11(2):199-208. PubMed ID: 27909950 [TBL] [Abstract][Full Text] [Related]
12. Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy. Estfan B; Byrne M; Kim R Am J Clin Oncol; 2013 Aug; 36(4):319-24. PubMed ID: 22547010 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of Sorafenib for Advanced Hepatocellular Carcinoma and Prognostic Factors. Li J; Wang L; Cong N; Shi C; Bu W; Song J; Chen H Hepatogastroenterology; 2014 Jun; 61(132):954-7. PubMed ID: 26158148 [TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. Wörns MA; Weinmann A; Pfingst K; Schulte-Sasse C; Messow CM; Schulze-Bergkamen H; Teufel A; Schuchmann M; Kanzler S; Düber C; Otto G; Galle PR J Clin Gastroenterol; 2009; 43(5):489-95. PubMed ID: 19247201 [TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy: a Korean multicenter study. Lee S; Kim BK; Kim SU; Park SY; Kim JK; Lee HW; Park JY; Kim DY; Ahn SH; Tak WY; Kweon YO; Lee JI; Lee KS; Kim HJ; Han KH J Gastroenterol Hepatol; 2014; 29(7):1463-9. PubMed ID: 25273508 [TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON. Kudo M; Ikeda M; Takayama T; Numata K; Izumi N; Furuse J; Okusaka T; Kadoya M; Yamashita S; Ito Y; Kokudo N J Gastroenterol; 2016 Dec; 51(12):1150-1160. PubMed ID: 27106231 [TBL] [Abstract][Full Text] [Related]
17. The Impact of Combined Transarterial Chemoembolization on the Overall Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib. Chen L; Su H; Shao H; Xu K; Liang S; Liu J Hepatogastroenterology; 2014 May; 61(131):802-8. PubMed ID: 26176077 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. Bruix J; Raoul JL; Sherman M; Mazzaferro V; Bolondi L; Craxi A; Galle PR; Santoro A; Beaugrand M; Sangiovanni A; Porta C; Gerken G; Marrero JA; Nadel A; Shan M; Moscovici M; Voliotis D; Llovet JM J Hepatol; 2012 Oct; 57(4):821-9. PubMed ID: 22727733 [TBL] [Abstract][Full Text] [Related]
19. Alternative treatments in advanced hepatocellular carcinoma patients with progressive disease after sorafenib treatment: a prospective multicenter cohort study. Nakano M; Tanaka M; Kuromatsu R; Nagamatsu H; Satani M; Niizeki T; Okamura S; Iwamoto H; Shimose S; Shirono T; Noda Y; Koga H; Torimura T; Oncotarget; 2016 Sep; 7(39):64400-64409. PubMed ID: 27462865 [TBL] [Abstract][Full Text] [Related]
20. Real-Life Experience of Sorafenib Treatment for Hepatocellular Carcinoma in Korea: From GIDEON Data. Kim DY; Kim HJ; Han KH; Han SY; Heo J; Woo HY; Um SH; Kim YH; Kweon YO; Lim HY; Yoon JH; Lee WS; Lee BS; Lee HC; Ryoo BY; Yoon SK Cancer Res Treat; 2016 Oct; 48(4):1243-1252. PubMed ID: 26910470 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]